Triple Therapy Benefit in Chronic Obstructive Pulmonary Disease

MeiLan K. Han, MD


August 26, 2020

Treatment for chronic obstructive pulmonary disease (COPD) traditionally has been inhaled corticosteroids, long-acting beta agonists, or long-acting muscarinic antagonists. These agents can be used alone or in combination, depending on the severity of patient symptoms, eosinophil count, and exacerbation risk. Dr MeiLan Han, of the University of Michigan, discusses results from the IMPACT and ETHOS trials, which show that triple therapy provides benefit in highly symptomatic, high-risk patients who are not responding to dual therapy. Patients taking triple therapy had fewer COPD exacerbations, fewer symptoms, lower rates of hospitalization, and improved lung function.

Dr Han also reports that a survival benefit was seen with triple therapy in both IMPACT and ETHOS.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.